Business Wire

Subscribe to Business Wire: eMailAlertsEmail Alerts
Get Business Wire via: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

News Feed Item

Signet Accel Announces Curt Weber as National Sales Director of Pharma Division

Software and services company Signet Accel announced today that Curt Weber joined the company as National Sales Director of its pharma division. With more than two decades in healthcare, Weber will expand Signet Accel’s portfolio of national and international biopharma clients and support the executive team in further establishing the brand as a leader in healthcare technology and data integration.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171110005443/en/

Curt Weber, National Sales Director of the pharma division for Signet Accel. (Photo: Business Wire)

Curt Weber, National Sales Director of the pharma division for Signet Accel. (Photo: Business Wire)

“Signet Accel has the answer, finally, to the question of interoperability and data integration,” Weber said. “Throughout my healthcare career, it has been one of the biggest challenges that my clients have faced. I worked for a large EMR company but ran into roadblocks where disparate data couldn’t connect. I’ve also worked for a data analytics company, and while powerful, the tools are only as effective as the data you put into it. Avec® delivers the solution to ensure both EMRs and analytics tools reach their maximum potential.”

Weber’s extensive experience in HIT and pharma sales includes positions with Cerner, GlaxoSmithKline, RBC Medical Innovations, Morgan-Hunter Healthcare, Inc. and most recently, IBM Watson Health Analytics.

“Curt is an incredibly steadfast, principled professional, with a genuine desire to build lasting relationships,” said Signet Accel Executive Vice President of Sales and Marketing Brenda Berry. “Not only does his career history speak for itself, he’s passionate about our mission and end goal of data integration with Avec: improving care and discovery.”

Avec®, a federated data integration platform, is the company’s flagship product. Avec connects disparate databases across healthcare verticals, allowing researchers to identify patterns and trends over a large patient population and offering comprehensive insight into both research and patient treatment. Robust repositories of connected data are a key resource in realizing the promise of precision medicine, a research effort aimed at improving health and treating disease by accounting for patients’ individual differences.

“It’s so great to be back in a world where we are talking about patients again,” Weber said. “The team here is patient-driven in its approach, with diverse skill sets and winning attitudes. I’m in awe of the skill and talent at Signet Accel and I can’t wait to learn and grow with this team.”

Weber joins an expanding national sales team. With its growing client base and deepening client engagements, Signet Accel is also doubling its physical footprint to accommodate a 60 percent increase in staff in 2017.

About Signet Accel

Signet Accel’s Avec® platform is true interoperability realized in healthcare. As the sole alternative to traditional, centralized data management solutions, Avec® delivers the industry's only purpose-built commercial federated data integration platform, developed and refined over 12 years at The Ohio State University. Signet Accel’s software products and services power the work of consortia, institutions, and health professionals around the world with unmatched security, sharing capability and speed of discovery —advancing academic research, achieving meaningful use objectives, and enabling the continuum of care. Learn how to make your data meaningful and achieve true interoperability at SignetAccel.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.